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ABSTRACT.
Purpose: To study the genetic aetiology and phenotypes of retinal degeneration
(RD) in Finnish children born during 1993–2009.
Methods: Children with retinal degeneration (N = 68) were investigated during
2012–2014 with a targeted gene analysis or a next-generation sequencing (NGS)
based gene panel. Also, a full clinical ophthalmological examination was performed.
Results: The cohort covered 44% (68/153) of the Finnish children with inherited
RD born 1993–2009. X-linked retinoschisis, retinitis pigmentosa, Leber
congenital amaurosis and cone–rod dystrophy were the most common clinical
diagnoses in the study group. Pathogenic mutations were found in 17 retinal
genes. The molecular genetic aetiology was identified in 77% of the patients (in
77% of the families) analysed by NGS method. Several founder mutations were
detected including three novel founder mutations c.148delG in TULP1,
c.2314C>R (p.Gln772Ter) in RPGRIP1 and c.533G>A (Trp178Ter) in TYR.
We also confirmed the previous tentative finding of c.2944 + 1delG in GYCU2D
being the most frequent cause of Leber congenital amaurosis (LCA) in Finland.
Conclusions: Globally, RD is genetically heterogeneous with over 260 disease
genes reported so far. This was shown not to be the case in Finland, where the
genetic aetiology of RD is caused by a small group of genes, due to several
founder mutations that are enriched in the population. We found that X-
chromosomal retinoschisis constitutes the major group in Finnish paediatric RD
population and is almost exclusively caused by two founder mutations. Several
other founder mutations were detected including three novel founder mutations.
All in all, the genetic aetiology of 77% of families was identified which is higher
than previously reported from other populations, likely due to the specific
genomic constitution of the Finns.
Key words: blindness – founder mutation – molecular genetic aetiology – next-generation
sequencing – paediatric retinal degeneration – visual impairment
Acta Ophthalmol.
ª 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd
doi: 10.1111/aos.14128
Introduction
In western countries, the inherited and
neuro-ophthalmological disorders are
the most prevalent causes for vision
impairment (VI) in childhood. VI
aﬀects the child0s development, educa-
tion and the care to be provided by
families and professionals. The associ-
ated lifelong burden of disability is
signiﬁcant and has high economic
costs.
The prevalence of VI in children has
been studied in diﬀerent populations,
and it has been shown to vary from 10–
41/100 000 (Foster & Gilbert 1992) to
181/100 000 (Arnaud et al. 1998). The
prevalence of VI in children has also
been studied in Finland (Rudanko &
Laatikainen 2004), where it was shown
to be 49/100 000 in children born
during 1972–1989. At the time, the
most frequent ophthalmological diag-
noses in the children were ocular mal-
formations (34%), retinal diseases
(31%) and neuro-ophthalmological
disorders (26%). Further, VI was asso-
ciated with genetic factors in 42% of all
children and 53% in the full-terms
(Rudanko & Laatikainen 2004).
The recent advances in sequencing
technologies, especially next-genera-
tion sequencing (NGS) techniques,
have dramatically changed our ability
to identify causative mutations in
genetic diseases. Next-generation
1
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sequencing has been shown to be
extremely eﬃcient at identifying causa-
tive genes in retinal degeneration (RD),
which is known to be a genetically very
heterogeneous condition (Farrar et al.
2017). We wanted to ﬁnd out the
genetic aetiologies of RD in children
in Finland. We hypothesized that NGS
method might reveal new founder
mutations in Finnish RD children.
Patients and Methods
The ethical tenets for human scientiﬁc
research according to the Declaration
of Helsinki (2000) (World Medical
Association General Assembly, 2001)
were adhered, and the research plan
was approved by the Ethical Board of
the Medical Faculty of the University
of Helsinki. A permission for fulﬁlling
the research plan was admitted by the
National Institute for Health and Wel-
fare in Finland (THL).
Medical records were received from
University and Central hospitals, Visio
low vision rehabilitation centre, the
Finnish Register of Visual Impairment
(FRVI), the Register of Congenital
Malformations and the Medical Birth
Register. Additional information con-
cerning relatives and their diseases was
acquired with a questionnaire.
Prior to investigations, after being
well informed on the purpose and
implications of the study, every partic-
ipating patient signed a consent by
themselves if they were aged 15 years
or over, and by their guardian if they
were below 15 years. A separate con-
sent concerning genetic analysis was
also signed by the patient or the
guardian.
There were 874 children with VI
born 1993–2009 at the Finnish Register
of Visual Impairment (FRVI) including
153 children with various types of RD
as the primary cause of VI. These 153
patients from 2 to 18 years of age were
invited to participate in the study.
Written information about the study
was delivered to patients and families
attending Visio, Low Vision Research
Centre in Helsinki, and the Ophthal-
mological Departments of the Univer-
sity and Central hospitals throughout
the country. We also advertised this
study in a journal published by the
retinitis pigmentosa patient organisa-
tion.
Families contacted researchers by
phone or letter, and 75 families were
invited for a ﬁrst visit into Visio. All of
them were of Finnish origin. During
the ﬁrst visit, complete ophthalmolog-
ical examination was conducted, and
the medical records were examined for
checking the fulﬁlment of the recruit-
ment criteria. The children with an
obvious genetic RD as the primary
cause of visual impairment were
selected to participate in the cohort.
Some patients with severe motor and
cognitive impairment were excluded
because of co-operational reasons.
Children with persistent fetal vitreous,
choroid coloboma, foveal hypoplasia,
congenital nystagmus and high myopia
without retinal degeneration that is
congenital birth defects and malforma-
tions without any signs of dystrophic
retinal structure were excluded. The
ﬁnal size of the study group was 68
children from 53 families.
The 68 patients were examined oph-
thalmologically, a detailed family his-
tory was taken, medical records were
examined and an EDTA-blood sample
taken for genetic analysis if the molec-
ular genetic aetiology was unknown. In
addition, the DNA samples were taken
from parents, siblings and sometimes
also from other relatives. When neces-
sary or informative, also parents,
grandparents, brothers and sisters were
examined ophthalmologically.
The ophthalmological examinations
included assessment of visual acuity
(ETDRS LogMAR letters or symbols
for suitable far and near distances),
contrast sensitivity (low contrast Sloan
letters or symbols for suitable far and
near distances), colour vision (Ishihara
Pseudo Isochromatic Plates, Farns-
worth’s Panel D-15), binocularity,
stereo vision (Random Dot (Butterﬂy)
Stereotest), assessment of ocular
motor functions, refraction, Haag
Streit slit lamp biomicroscopy and
ophthalmoscopy. Heidelberg Spec-
tralisR HRA+OCT MulticolorTM with
BluePeak (Heidelberg Engineering
GmbH, Germany) was used for fun-
dus photography, optical coherence
tomography and autoﬂuorescence
imaging. Visual ﬁelds were tested with
Goldmann kinetic perimeter (V/4a, II/
4a) and Haag Streit Octopus 101
dynamic perimeter (dM2, central 30
degrees from ﬁxation). Due to vast
diﬀerences in visual functions of visu-
ally impaired children, a large selec-
tion of vision tests was used for
detecting the best picture of the child0s
vision during various tasks and light-
ing conditions.
The targeted gene tests were per-
formed using Sanger sequencing,
MLPA analysis or minisequencing for
founder mutations in X-linked
retinoschisis. Due to unspeciﬁc pheno-
type, samples from 36 families were
sent to a NGS-based gene panel anal-
ysis (see below). The mutations
detected with NGS were conﬁrmed by
Sanger sequencing. The samples from
aﬀected siblings and parents were anal-
ysed with a targeted mutation test to
determine the segregation and the
phasing of the mutated alleles.
Next-generation sequencing proce-
dure was performed as follows. Enrich-
ment was performed with a custom
design (Retinal dystrophy v2) Sure
Select Custom Target enrichment kit
(Agilent) for the Hiseq 2500 (Illumina)
system, following the manufacturer0s
protocols. The target enrichment
design consists of the coding region of
transcripts including the immediate
splice sites ( 5 bases) for 105 genes
associated with retinal dystrophy listed
Table 1. Retinal diagnoses and sex distribution of children with visual impairment born from 1993
through 2009 (N = 68)
Ophthalmic diagnosis
All children†
(N = 68)
Families
(N = 53)
Males
(N = 45)
Females
(N = 23)
Retinoschisis, juvenile x-linked 20 16 20 0
Retinal pigmentary degeneration 14 12 5 9
Usher syndrome, type 3 2 2 1 1
Leber congenital amaurosis 15 11 8 7
Cone-rod dystrophy 11 6 10 1
Neuronal ceroid lipofuscinosis 2 2 1 1
Achromatopsia 2 2 0 2
Stargardt disease 1 1 0 1
Albinism, oculocutaneous 1 1 0 1
†M/F ratio 1.96.
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in the supplement. The samples were
sequenced using a HiSeq 2500 (Illu-
mina), according to manufacturer0s
protocols. Sequence data were mapped
with GenomeAnalysisToolKitLite-
v2.0.39 (GATK) and with hg19 human
genome as a reference. Known poly-
morphisms were subsequently ﬁltered
out of the data obtained using bioin-
formatic analysis. 99.4% of the target
coding region of the transcripts was
covered to a minimum depth of 50X.
The 105 genes analysed in the NGS
panel are listed in Appendix S1. Ala-
mut Visual software was used to anal-
yse the meaning of detected variants.
Alamut uses information from diﬀerent
public databases such as NCBI, EBI
and UCSC, as well as other sources
including gnomAD, ESP, Cosmic or
ClinVar. Moreover, Alamut Visual
integrates several missense variant
pathogenicity prediction tools and
algorithms such as SIFT, PolyPhen,
AlignGVGD or MutationTaster.
Results
After a thorough ophthalmological
examination, a clinical diagnosis was
established for each patient. These
clinical diagnoses are presented in
Table 1 as well as the sex distribution
of the patients. There were altogether
68 patients (44 males and 24 females)
from 53 families in the cohort. The
three biggest groups of patients were
X-linked juvenile retinoschisis (XLRS)
with 29% (20/68) of the patients and
30% (16/53) of the families, retinitis
pigmentosa with 21% (14/68) of the
patients and 22% (12/53) of the fam-
ilies, and Leber congenital amaurosis
with 22% (15/68) of the patients and
20% (11/53) of the families. 16% (11/
63) of the patients had cone–rod dys-
trophy, and 6% (6/53) of the families
had a member with cone–rod dystro-
phy. In addition, some other diagnoses
were found in the cohort (see Table 1).
The genetic aetiology was identiﬁed
in 77% (41/53) of all the families and
77% (52/68) of all the patients. 47%
(25/53) of the families had a causative
mutation in NGS analysis, and 30%
(16/53) of the families had a RS1
mutation. Findings of unknown signif-
icance were received in 13% (7/53) of
all families and in 10% (8/68) of all
children. In 9% of the families and
children no genetic ﬁndings were iden-
tiﬁed.
The NGS gene panel with 105 RP
genes was used in cases of 41 children
from 33 families, which revealed the
genetic aetiology of RDs in 63% of the
children (26/41) and in 64% of the
families (21/33).
The XLRS comprised the largest
group of patients and the molecular
aetiology was found in all cases. 60%
(12/20) patients had a c.214G>A
(p.Glu72Lys) mutation in RS1 gene,
25% (5/20) had a c.325G>C
(p.Gly109Arg) mutation, two had a
c.533G>A (p.Gly178Asp) mutation
and one had a deletion of the exon 1
in RS1 gene.
The genetic results of this study are
presented in Table 2. Interestingly, in
LCA patients, a homozygous
c.2944 + 1deIG mutation in GUCY2D
gene was found to occur in ﬁve families
with seven patients (cases 1–5).
c.2944 + 1deIG mutation in GUCY2D
gene accounted for 70% (14/20) of the
Finnish LCA-associated alleles in this
study.
The allele frequencies of all the
missense and nonsense mutations
detected in this study were compared
in the gnomAD database (Lek et al.
2016) between the Finnish population
and European, non-Finnish popula-
tion. Interestingly, seven of the disease
alleles were more prevalent in the
Finnish population than elsewhere in
the Europe. They are listed in Table 3.
The list includes previously reported
founder mutations c.567T>G
(p.Tyr189Ter) in CLRN1 (Joensuu
et al. 2001), c.214G>A (p.Glu72Lys)
and c.325(p.Gly109Arg) in RS1 (Huo-
paniemi et al. 1999), and 2.8 kb dele-
tion in CLN3 (1998), and most
recently, c.1155T>A (p.Cys385Ter) in
EYS (Avela et al. 2018), whereas
c.148delG in TULP1, c.2314C>T
(p.Gln772Ter) in RPGRIP1, and
c.533G>A (p.Trp178Ter) in TYR were
novel ﬁndings.
The interesting phenotypes and the
genotypes of the two Finnish EYS
patients are described in more detail
in Table 4, and their spectral fundus
images are presented in Fig. 1. In
addition, two RP siblings were found
to be carriers of c.1155T>A, but
MLPA analysis of their EYS gene did
not reveal any large deletion or dupli-
cations. As the ophthalmological pre-
sentations in RD are overlapping, it is
impossible to know whether a missing
other mutation is more likely than aT
ab
le
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causative change in entirely diﬀerent
gene.
Mutation c.148delG in TULP1 was
also found to be enriched in the Fin-
nish population as the allele frequency
was 0.002882 in Finland, and 0 in
European, non-Finnish population
(Table 3). A homozygous c.148delG
mutation in TULP1 gene was found
in two siblings with early-onset RD/
RCD (case 16).
One of the enriched alleles was
c.2314C>T (p.Gln772Ter) in RPGRIP1
gene. We detected it in a compound
heterozygous state in two LCA siblings
(case 6).
One patient with oculocutaneous
albinism was a compound heterozygote
for c.533G>A (p.Trp178Ter) and
c.650G>A (p.Arg217Gln) in TYR gene
(case 24). c.533G>A was found to be
more frequent in Finland than else-
where in Europe, whereas no diﬀerence
in the occurrence of c.650G>A was
detected between the populations of
Finland and the rest of Europe.
Altogether, pathogenic mutations
were found in 17 genes in 77% of the
families (41/53) participating in the
study. A variant of unknown signiﬁ-
cance (VUS) or a carriership of a RD
mutation was found in seven families.
No pathogenic mutation was detected
in ﬁve families (Table 2).
Discussion
We present a cohort of 68 Finnish
children born in 1993–2009 with inher-
ited RD, based on our investigations
for the genetic aetiology of their dis-
ease. This cohort can be considered as
a representative sample about Finnish
children with RD, born in 1993–2009
and registered at the FRVI, as 46% of
such children participated in the study.
80% of the children were from the
southern, western and central Finland,
while only 20% came from the north-
ern and north-eastern country reﬂect-
ing the fact that most of the people live
in the southern and south-western part
of the Finland. There are still some
sub-isolates in northern and north-
eastern parts of the country which are
under-represented in this cohort, and
their RD alleles still remain to be
discovered.
In this study, 29% of the patients
had XLRS comprising the largest
patient group. According to De La
Chappelle et al. (1994) the XLRS
prevalence is greater than 1:17 000 in
Finland which is in line with our
results, that is 20 cases, 46% coverage,
and 1, 006, 006 births during 1993–
2009 (Gissler et al. 2017). The high
amount of males in this study is
explained by the large number of
XLRS patients in Finland.
X-linked juvenile retinoschisis is
enriched in the Finnish population
(Table 3) and is one of the around 40
diseases of the Finnish Disease Her-
itage (Norio 2003), which are more
prevalent in Finland than elsewhere.
The Finnish Disease Heritage includes
other eye diseases as well namely
choroideraemia and hyperornithi-
naemia with gyrate atrophy of choroid
and retina (HOGA), which were not
seen in this study. This could be due to
regional diﬀerences or to sample size.
Instead this cohort included two cases
of Usher syndrome type 3, impairing
both vision and hearing, and two cases
of a severe neurological disorder, neu-
ronal ceroid lipofuscinoses (INCL,
vLINCLFin, JNCL), all of them are
Finnish diseases. The Finnish Disease
Heritage has evolved as a consequence
of the Finnish population history,
especially small groups of original set-
tlers, and geographical isolation have
led to enrichment of certain disease
mutations in the population. These
common mutations are called founder
mutations.
Several founder mutations were
identiﬁed in this study. The mutations
c.214G>A and c.325G>C in RS1,
c.567T>G in CLNR1 and 2.8 kb dele-
tion in CLN3 have been described
previously (The International Batten
Disease Consortium 1995; Huopaniemi
et al. 1999; Joensuu et al. 2001).
Hanein et al. 2002 have reported
c.2944 + 1delG in GUCY2D in three
Finnish LCA patients. We were able to
conﬁrm that c.2944 + 1delG is a foun-
der allele, as it accounted for 70% (14/
20) of the LCA-alleles in this cohort.
Recently, c.375C>G p.(Cys125Trp)
in CERKL and c.1155T>A
(p.Cys385Ter) in EYS were reported
to be founder mutations in a Finnish
cohort of adult RD patients (Avela
et al. 2018). The total absence of
CERKL patients and the relatively
small number of EYS patients in this
paediatric cohort most likely reﬂects
the typical adolescence or adult onset
of those diseases (Pierrottet et al. 2014,
and Avela et al. 2018). EYS mutations
have been reported in arRP in several
European countries, and in Japan and
China with variable phenotypes (Lit-
tink et al. 2010; Chen et al. 2015; Gu
et al. 2016).
Table 3. Disease alleles enriched in the Finnish population, and detected in this pediatric retinal degeneration cohort
Gene
Mode of
inheritance Mutation
Allele frequence in Finnish
population from gnomAD
Allele frequence in
European non-Finnish
population from gnomAD Original reference
CLRN1 ar c.567T>G (p.Tyr189Ter) 0.006904 (178/25782) 0.0001187 (15/126344) Joensuu et al. (2001)
EYS ar c.1155T>A (p.Cys385Ter) 0.006336 (163/25728) 0.0002780 (35/125884) Avela et al. (2018)
TULP1 ar c.148delG 0.002882 (36/12490) 0 (0/36614) Avela et al. (2018), and this report
RPGRIP1 ar c.2314C>T (p.Gln772Ter) 0.0002245 (1/4454) 0 (0/38550) This report
TYR ar C.533G>A (p.Trp178Ter) 0.0001551 (4/25788) 0 (0/126648) This report
RS1 X-linked c.214G>A (p.Glu72Lys) 0.0001216 (2/16443) 0 (0/80126) Huopaniemi et al. (1999)
RS1 X-linked c.325G>C (p.Gly109Arg) 0.0001826 (3/16432) 0 (0/79858) Huopaniemi et al. (1999)
CLN3 ar 2.8 kb deletion NA NA The International Batten
Disease Consortium (1995)
GUCY2D ar c.2944 + 1deIG NA, accounts for 50% of
LCA cases in this report
NA Hanein et al. (2004), and this
report
ar = autosomal recessive, NA = not available, X-linked = X-chromosomal.
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The two cases with EYS mutations
in this study presented with rather
similar phenotypes, except for the sev-
ere central macular oedema (CME),
which was seen in the fundus of the
female patient. Rather high prevalences
of CME have been reported in RP (e.g.
Hajali et al. 2008). In this study group,
CME was present in 41% (7/17) of the
patients with RP and Usher syndrome,
being consistent with recent scientiﬁc
reports.
Interestingly, one mother of two
visually impaired siblings without a
diagnosis was homozygous for
c.1155T>A EYS mutation. She has a
so-called ‘classic’ RP phenotype with
typical bone spicule pigmentations.
The father of these siblings was
unavailable for the examinations, but
he or anyone else in the family was not
known to be visually impaired. The
phenotypes of our paediatric EYS
cases (8 and 9) diﬀered from the
mother’s classic one, in part due to
the longer duration of the mother’s RP
with heavy pigment migration from her
atrophic retinal pigment epithelium
(RPE) into retinal layers. However,
by MultiColour Green and Infrared
Reﬂectance imaging (30°), the fundi of
cases 8 and 9 were more reﬂective than
expected (Fig. 1), probably due to
notable shortage or loss of pigment in
the course of RPE atrophy. Further
studies are needed for clarifying the
diversity and evolution of phenotypes
of EYS mutations in the Finnish pop-
ulation.
Interestingly, we found three novel
founder mutations (Table 3). One of
them was c.148delG in TULP1 causing
ar-LCA and early-onset RD (EORD).
In TULP1-associated LCA and
EORD, rods and cones are aﬀected
very early, due to prenatal retinal
maldevelopment and rapid postnatal
degeneration. Functional rods are usu-
ally not found at birth, and macular
cones are insensitive (Jacobson et al.
2014). Nystagmus and night blindness
appear during the ﬁrst weeks of life and
are important signs for initiating oph-
thalmological examinations.
Our patients with TULP1 homozy-
gous mutation (cases 16a and 16b,
Table 2) were two male siblings with
RCD/early-onset RD, aged 6 years
and 4 years at the onset of examina-
tions. Their ages of clinical diagnosis
were 3 years and one year, respectively,
and their phenotypes very much like
previously reported (Ajmal et al. 2012).
The older sibling (case 16a) had severe
low vision with BCVA 0.20 OD and
0.12 OS, tritan colour vision defects,
peripheral constrictions in the visual
ﬁelds (VFs), large central-pericentral
scotomas and small functional spots
remaining in the VF centre. Thin reti-
nal blood vessels with some occluded
ﬁbrosed vessels were seen in the fundi.
Optic discs with white peripapillar
cuﬀs, general RPE atrophy, retinal
thinning with granular pigmentation
and pigment dots, and maculopathy
with some foveal dysplasia, light peri-
foveal annular rings and large choroi-
dal vessels well discernible under
thinned retinal layers were the
Fig. 1. Spectral fundus images of two patients with retinitis pigmentosa associated with
homozygous EYS gene mutations. First line: case 8 with severe degeneration in foveal–perifoveal
photoreceptors, RPE and choriocapillaris, and with high cystic macular oedema (IR 30 & OCT
images). Second line: case 8 with degeneration in foveal and perifoveal photoreceptors, RPE and
choriocapillaris, but no cystic macular oedema (IR 30 & OCT images). Third line: case 8 and case
9 with a hyperﬂuorescent ring of lipofuscin accumulated in the central RPE of both patients, in
consequence of RPE degeneration (BAF images).
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prevailing features of the phenotype.
The ERGs were undetectable.
RPGRIP1 mutations lead into a
severe nonsyndromic retinal ciliopathy,
typical to Leber congenital amaurosis
(Khan et al. 2013). The phenotypes of
our patients (cases 6, Table 2) were
similar to those in previous reports.
Signs of poor vision and nystagmus
had been noticed within the ﬁrst
3 months in both siblings, and ERG
responses had been nonrecordable
since birth. The ocular fundi had
looked normal during the ﬁrst year of
life, but thereafter, rapidly progressive
retinal degeneration led into most sev-
ere atrophy and functional blindness.
The reported BCVAs were at the level
of light perception (LP).
TYR mutations cause oculocuta-
neous albinism type1 (OCA1) charac-
terized by nystagmus,
hypopigmentation of skin and hair, iris
translucency, low levels of retinal pig-
ment, foveal hypoplasia and choroidal
blood vessels well discernible through
light retinal layers during ophthal-
moscopy. As most Finnish children
have white hair and pale skin, the
diagnosis of ocular or oculocutaneous
albinism is not as obvious in Finnish as
in some other populations. One of our
patients was suspected to have oculo-
cutaneous albinism and was shown to
have c.650G>A (p.Arg217Gln) and
c.533G>A (p.Trp178Ter) in TYR. The
latter of the mutations is enriched in
the Finnish population according to
gnomAD database (Table 3). At the
age of 9 years, our female patient (case
24) had horizontal nystagmus since
birth, BCVA of 0.08 OD and 0.08
OS, rather high binocular hyperopia
and astigmatism, alternating esotropia,
photophobia, yellowish fundi, some
macular dysplasia and foveal hypopla-
sia with central and perisentral sco-
tomas by Goldmann perimetry. Slight
brown pigment was discernible in her
eyebrows, eyelashes, irises and fundi.
Obviously, she has some melanin syn-
thesis in her RPE melanosomes, with
low function of tyrosinase enzyme, and
thus the diagnosis can be further
deﬁned to OCA1B.
Despite many founder mutations,
nonfounder gene defects were also
diagnosed (RDH12, RHO, PRPF8,
RPGR, ABCA4, CRX, CEP290,
CNGB3) indicating some genetic
heterogeneity among Finnish children
with retinal degeneration, even though
to a lesser extent than elsewhere in
Europe.
To conclude, the most common
clinical diagnoses for retinal degenera-
tion in Finnish children in this cohort
were XLRS, RP, LCA, EO-RCD and
CRD. The unusual population history
of Finland is reﬂected in the ﬁndings of
this study. Several founder mutations
were identiﬁed, including three new
founder mutations, c.148delG in
TULP1, c.2314C>R (p.Gln772Ter) in
RPGRIP1, and c.533G>A (Trp178Ter)
in TYR. We also conﬁrmed the previ-
ous tentative ﬁnding of c.2944 + 1delG
being a frequent cause of LCA in
Finland. The genetic aetiology was
identiﬁed in 77% of the families. This
is higher than reported from other
populations, likely due to the founder
mutations.
The detection rate of signiﬁcant
pathogenic variants would have been
somewhat higher by whole exome
sequencing or by additional special
molecular laboratory techniques, like
copy number variant analysis, long range
PCR ampliﬁcation of hard-to-sequence
targets or mutation-speciﬁc analysis of
deep intronic mutations, which were not
possible to use in this cohort.
Exact genetic aetiology allows accu-
rate genetic counselling for the beneﬁt
of involved families. This knowledge
also allows us to recognize the families
who can take advantage from future
gene therapy treatments.
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